Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cochlear implants cases in Virginia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 23% on average (17 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 83 | 24% |
| 2020 | 2 | 84 | 28% |
| 2021 | 3 | 105 | 33% |
| 2022 | 3 | 84 | 37% |
| 2023 | 2 | 89 | 40% |
| 2024 | 3 | 115 | 42% |
| 2025 from claims | – | 111 90–130 | 43% |
| 2026 forecast | – | 118 93–149 | 44% |
| 2027 forecast | – | 125 93–166 | 44% |
| 2028 forecast | – | 133 94–183 | 45% |
| 2029 forecast | – | 141 96–202 | 46% |
| 2030 forecast | – | 149 98–221 | 46% |
Cochlear implantation, children and adults. Professional codes (what the surgeon bills): CPT 69930.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Virginia; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 9 | 349+4.4%/yr | +4.4%/yr | 0.2 | 30% | 300 in 2030−2.5%/yr |
| Texas | 9 | 288+1.6%/yr | +1.6%/yr | 0.1 | 13% | 330 in 2030+2.2%/yr |
| Tennessee | 7 | 205+8.7%/yr | +8.7%/yr | 0.3 | 28% | 290 in 2030+6.2%/yr |
| North Carolina | 5 | 192+9.9%/yr | +9.9%/yr | 0.2 | 21% | 300 in 2030+7.5%/yr |
| South Carolina | 6 | 142+4.7%/yr | +4.7%/yr | 0.2 | 17% | 310 in 2030+14%/yr |
| Georgia | 4 | 121+12%/yr | +12%/yr | 0.1 | 0% | 230 in 2030+11%/yr |
| Maryland | 4 | 116+2.8%/yr | +2.8%/yr | 0.1 | 0% | 100 in 2030−2.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 23 | 2,887−4.8%/yr | −4.8%/yr | 2.80.5× | 80% | 2,650 in 2030−1.4%/yr |
| Ear tubes & middle ear surgery | 3 | 291−2.9%/yr | −2.9%/yr | 0.30.8× | 60% | 280 in 2030−0.5%/yr |
| Sleep apnea & airway implants | 4 | 141+51%/yr | +51%/yr | 0.10.5× | 11% | 190 in 2030+5.4%/yr |
Cochlear implants in every state, and its device makers · Every procedure market in Virginia · Every state · Compare with Florida
Integra LifeSciences leads with 47% of company spending on these surgeons in 2025, +10 pts on 2024.
In 2025, 7 companies reported engagement with Virginia’s surgeons worth $6,669 in consulting, speaking, meals and travel tied to these products, about $2,223 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 15 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.